The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.
In PLOS this week: resource to track Mendelian disease-related variants in dogs, microRNAs linked to atrial fibrillation in surgical patients, and more.
Molecular analysis of metastatic CRC in the liver has identified three molecular subtypes that can be coupled with clinical risk scores to inform patient risk.
The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.
The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
In PLOS this week: microRNA helps M. tuberculosis escape the immune system, application of genome-scale metabolic models to drug design, and more.
Six microRNAs appeared to be present at enhanced levels in cerebrospinal fluid from symptom-free individuals with characteristic Huntington disease gene expansions.
In PNAS this week: multi-omic analysis of Atlantic Ocean samples, miR-351 linked to hepatic fibrosis during Schistosoma infection, and more.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.